Proactive - Interviews for investors
Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics
Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care.
The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events.
Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales.
While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX.
Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk.
Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success.
Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan.
#proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk
#LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason
AI
